Browse studies

Find your next paid study

20 recruiting studies matching your filters

Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surg…

Glaucoma, Open-angleOcular Hypertension (OHT)Phacoemulsification Cataract Surgery

Estimated

~$10 – $8,750

Glaukos CorporationNCT06848946

Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Open Angle Glaucoma (OAG)Ocular Hypertension (OH)

Estimated

~$10 – $1,050

Glaukos CorporationNCT07400926

Observational

A Randomized Controlled Trial Comparing Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma

This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Bo…

Open-angle Glaucoma (OAG)Ocular Hypertension (OHT)

Estimated

~$10 – $6,250

Medical University of South CarolinaNCT07408154

Phase 3

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in partici…

CataractGlaucomaOcular Hypertension

Estimated

~$10 – $8,750

SpyGlass Pharma, Inc.NCT07218783

Observational

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotens…

Ocular HypertensionPrimary Open Angle Glaucoma

Estimated

~$10 – $7,500

59th Medical WingNCT05844384

Phase 3

A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioeq…

Glaucoma, Open-AngleOcular Hypertension

Estimated

~$10 – $8,750

Amneal Pharmaceuticals, LLCNCT05401357

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in red…

Primary Open Angle GlaucomaOcular Hypertension

Estimated

~$10 – $1,125

The Eye Institute of West FloridaNCT07390890

Phase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Open-angle GlaucomaOcular Hypertension

Estimated

~$10 – $8,750

Amneal Pharmaceuticals, LLCNCT06267274